ReviewDrugs & aging2014
A benefit-risk assessment of the use of proton pump inhibitors in the elderly.
Review in Drugs & aging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline.Canadian family physician Medecin de famille canadien · 2017Guideline
- Effectiveness of Interventions to Deprescribe Inappropriate Proton Pump Inhibitors in Older Adults.Drugs & aging · 2017Pooled it
- Trial
- The Aging Stomach: Clinical Implications ofInternational journal of molecular sciences · 2024Review
- Helicobacter pylori Eradication Treatment in Older Patients.Drugs & aging · 2024Review
- Proton pump inhibitors and cardiovascular risk: a critical review.Future cardiology · 2024Review
- Associated Factors to Efficacy and Tolerance of Immunotherapy in Older Patients with Cancer Aged 70 Years and Over: Impact of Coprescriptions.Drugs & aging · 2023Article
- Multiple Micronutrients, Including Zinc, Selenium and Iron, Are Positively Associated with Anemia in New Zealand Aged Care Residents.Nutrients · 2021Article
- Attitudes towards use of proton pump inhibitors among geriatricians in Italy.European geriatric medicine · 2019Article
- Predictors of Inappropriate Proton Pump Inhibitors Use in Elderly Patients.Current gerontology and geriatrics research · 2019Article
- The use of proton pump inhibitors among older adults with intellectual disability: A cross sectional observational study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2018Article
- Costs of medication in older patients: before and after comprehensive geriatric assessment.Clinical interventions in aging · 2018Article
- From Harmful Treatment to Secondary Gain: Adverse Event Reporting in Dyspepsia and Gastroparesis.Digestive diseases and sciences · 2017Article
- Long-term use of proton pump inhibitors among community-dwelling persons with and without Alzheimer's disease.European journal of clinical pharmacology · 2017Article
- Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Causes, Consequences and Public Health Implications of Low B-Vitamin Status in Ageing.Nutrients · 2016Review
- Proton pump inhibitor-induced Sweet's syndrome: report of acute febrile neutrophilic dermatosis in a woman with recurrent breast cancer.Dermatology practical & conceptual · 2015Article
- Article
- Evaluation of Prescribing Appropriateness and Initiatives to Improve Prescribing of Proton Pump Inhibitors at Vancouver General Hospital.The Canadian journal of hospital pharmacyArticle
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proton pump inhibitors (PPIs) are among the most commonly used drugs worldwide, and their intake increases with age. Despite a relatively safe profile, a range of studies have reported associations between use of PPIs and various adverse events. The most important adverse events, such as pneumonia, bone fractures, bacterial enteric infections, and diminished vitamin absorption are critically discussed in this review in view of the body of evidence, including underlying biological mechanisms, evidence of causality, and consistency. Most of the reported risks are relatively small and sometimes based on inconsistent evidence. For an individual patient, and particularly the elderly, it is relevant to question the indication of use and balance the benefit and potential harm of PPI therapy. This approach can minimize morbidity and reduce healthcare costs. In this review, the use and safety of PPIs among the elderly is described.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.